Drug Insights

Expert Tips for Searching Amitriptyline on Synapse

4 February 2024
2 min read

Amitriptyline Hydrochloride, a small molecule drug, is a reuptake inhibitor targets the monoamine transporters. Developed by Merck and first approved on April 7th, 1961, the drug is used to treat a range of conditions such as neuralgia, depressive disorder, and nocturnal enuresis. The drug works by preventing the reuptake of neurotransmitters, particularly serotonin and norepinephrine, which can lead to an increase in their concentration in the brain and subsequently enhance mood. Amitriptyline Hydrochloride is available in the form of oral tablets, which should only be used under the strict guidance of a healthcare provider. Patients must be aware of potential side effects such as dry mouth, constipation, and drowsiness, which can manifest in some individuals. The drug's administration should be closely monitored and individualized to ensure its safe and effective use. In conclusion, while Amitriptyline Hydrochloride presents an effective medication for managing certain neurological and mood disorders, patients must exercise caution and adhere to the recommended usage guidelines. Click on the image below to begin the exploration journey of Amitriptyline through the Synapse database!

图形用户界面, 应用程序, 电子邮件

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Celltrion USA Finalizes Application for Biosimilar Approval, Targets CT-P47 (ACTEMRA® Counterpart)
Latest Hotspot
3 min read
Celltrion USA Finalizes Application for Biosimilar Approval, Targets CT-P47 (ACTEMRA® Counterpart)
4 February 2024
Celltrion USA has finalized its application for a biosimilar approval, targeting CT-P47, a counterpart to the drug ACTEMRA® (tocilizumab).
Read →
Navigating Health Information: How to Use Synapse to Search for Diclofenac
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Diclofenac
4 February 2024
Diclofenac Sodium, a minuscule molecule drug, wields its prowess by targeting the COX enzyme as an inhibitor.
Read →
EU Commission Approves Takeda's HYQVIA® for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
Latest Hotspot
3 min read
EU Commission Approves Takeda's HYQVIA® for Chronic Inflammatory Demyelinating Polyneuropathy Treatment
4 February 2024
European Commission Sanctions Takeda's HYQVIA® for Ongoing Treatment in Chronic Inflammatory Demyelinating Polyneuropathy Cases.
Read →
Unveiling the Updated Email Alert Feature in Synapse Database: A Game-changer in Data Management
Feature Updates
6 min read
Unveiling the Updated Email Alert Feature in Synapse Database: A Game-changer in Data Management
2 February 2024
The powerful intelligence alert function of the Patsnap Synapse database makes it easy for you to complete various monitoring tasks.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.